Payment overview · 2025
General Payments
$281.55
14 reported records · 5 companies
Healthcare provider profile · identity verified
Vivian U Mapanao, MD
Allopathic & Osteopathic Physicians|Family Medicine · SUFFOLK, VA · NPI 1629233242
Verified facts
What the public records show
CMS Open Payments records show Vivian U Mapanao, MD received $281.55 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 57.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $162.74 | 57.8% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.55 | 15.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.29 | 12.5% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.02 | 7.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.95 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $281.55 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $88.34 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $88.34 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $74.40 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.40 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 130 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
130 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 567 | 180 |
| Atorvastatin Calcium | Atorvastatin Calcium | 495 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 391 | 130 |
| Losartan Potassium | Losartan Potassium | 366 | 98 |
| Montelukast Sodium | Montelukast Sodium | 263 | 92 |
| Omeprazole | Omeprazole | 260 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 213 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 212 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 48 |
| Carvedilol | Carvedilol | 153 | 45 |
| Tramadol Hcl | Tramadol Hcl | 151 | 36 |
| Lisinopril | Lisinopril | 150 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 63 |
| Furosemide | Furosemide | 142 | 46 |
| Ozempic | Semaglutide | 130 | 27 |
| Potassium Chloride | Potassium Chloride | 129 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 54 |
| Alendronate Sodium | Alendronate Sodium | 120 | 35 |
| Gabapentin | Gabapentin | 114 | 43 |
| Simvastatin | Simvastatin | 114 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 110 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 31 |
| Metformin Hcl | Metformin Hcl | 94 | 36 |
| Metformin Hcl Er | Metformin Hcl | 94 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 28 |
| Sertraline Hcl | Sertraline Hcl | 90 | 27 |
| Eliquis | Apixaban | 88 | 24 |
| Jardiance | Empagliflozin | 85 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 78 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 13 |
| Prednisone | Prednisone | 72 | 50 |
| Ezetimibe | Ezetimibe | 71 | 25 |
| Spironolactone | Spironolactone | 71 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 68 | 24 |
| Clonidine Hcl | Clonidine Hcl | 67 | 16 |
| Mounjaro | Tirzepatide | 64 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 62 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 35 |
| Trulicity | Dulaglutide | 61 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | 19 |
| Meloxicam | Meloxicam | 57 | 23 |
| Alprazolam | Alprazolam | 56 | 14 |
| Trazodone Hcl | Trazodone Hcl | 55 | 21 |
| Nystatin | Nystatin | 53 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 25 |
| Fluconazole | Fluconazole | 52 | 23 |
| Januvia | Sitagliptin Phosphate | 51 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 16 |
| Bupropion Xl | Bupropion Hcl | 48 | 16 |
| Synthroid | Levothyroxine Sodium | 47 | 14 |
| Topiramate | Topiramate | 45 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 11 |
| Novolog Flexpen | Insulin Aspart | 40 | 11 |
| Allopurinol | Allopurinol | 39 | 12 |
| Glipizide | Glipizide | 39 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | 11 |
| Telmisartan | Telmisartan | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | 12 |
| Atenolol | Atenolol | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | 11 |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Glimepiride | Glimepiride | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $281.55 · 14 records | ABBVIE INC. | BEXSERO, GVOKE HYPOPEN, MOUNJARO, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error